TABLE 2.
Animal survival after stem cell application
| First author | Animal model/Stem cell | Survival rate, n/N (%) | ||
|---|---|---|---|---|
| Treatment | Control | p value | ||
| Lee, 2004 (30) | Chicken embryo/Human ESCs | POD 3, NR | POD 4, NR | >0.05 |
| POD 5, NR | POD 6, NR | >0.05 | ||
| POD 7, NR | POD 8, NR | <0.05 | ||
| Lee, 2006 (31) | Chicken embryo/Human ESCs | POD 4, 15/19 (78.9%) | POD 4, 15/18 (83.3%) | 0.73 |
| POD 6, 15/21 (71.4%) | POD 6, 15/19 (78.9%) | 0.58 | ||
| POD 8, 15/23 (65.2%) | POD 8, 15/22 (68.2%) | 0.83 | ||
| Li, 2012 (33) | Wistar rat/Wistar rat BM‐MSCs | 152/195 (77.9%) | NA | NA |
| Li, 2014 (34) | Wistar rat/Wistar rat BM‐MSCs | 18/22 (81.8%) | NA | NA |
| Ma, 2015 (35) | Wistar rat/Wistar rat BM‐MSCs | 58/72 (80.6%) | NA | NA |
| Li, 2016 (36) | Wistar rat/Wistar rat BM‐MSCs | 69/134 (51.5%) | NA | NA |
| Wei, 2020a (37) | Wistar rat/Wistar rat BM‐MSCs | 30/30 (100%) | 23/23 (100%) | 1.00 |
| Wei, 2020b (38) | Wistar rat/Wistar rat BM‐MSCs | 32/32 (100%) | 28/28 (100%) | 1.00 |
| Turner, 2013 (48) | Lewis rat/Lewis rat AF‐NSCs | 20/37 (54.1%) | NA | NA |
| Dionigi, 2015a (39) | Sprague‐Dawley rat/Lewis rat AF‐MSCs | 28/82 (34.1%) | NA | NA |
| Feng, 2016 (41) | Sprague‐Dawley rat/Lewis rat AF‐MSCs and P‐MSCs | AF‐MSCs, 65/73 (89.0%) | 30/38 (78.9%) | 0.15 |
| P‐MSCs, 90/115 (78.3%) | 0.93 | |||
| Shieh, 2018 (42) | Sprague‐Dawley rat/Lewis rat AF‐MSCs | 70/78 (89.7%) | 62/66 (93.9%) | 0.77 |
| Lazow, 2020 (43) | Sprague‐Dawley rat/Lewis rat AF‐MSCs | 36/105 (34.3%) | 34/107 (31.8%) | 0.70 |
| Abe, 2019 (44) | Sprague‐Dawley rat/Human AF‐MSCs | 19/22 (86.4%) | 17/19 (89.5%) | 0.76 |
| Kajiwara, 2017 (45) | Sprague‐Dawley rat/3D skin from human AF‐derived iPSCs | 20/20 (100%) | NA | NA |
| Shieh, 2019 (46) | New Zealand rabbit/New Zealand rabbit AF‐MSCs | 10/35 (28.6%) | 5/15 (33.3%) | 0.74 |
| Fauza, 2008 (47) | Ovine/Mice cerebellum NSCs | 8/9 (88.8%) | 6/7 (85.7%) a | 0.85 |
| Saadai, 2013 (49) | Ovine/Human NCSCs derived from iPSCs | 2/2 (100%) | NA | NA |
| Wang, 2015 (50) | Ovine/Human P‐MSCs | 6/6 (100%) | 6/6 (100%) a | 1.00 |
| Brown, 2016 (51) | Ovine/Human P‐MSCs | 2/2 (100%) | 1/1 (100%) a | 1.00 |
| Vanover, 2019 (54) | Ovine/Human P‐MSCs | 19/22 (86.4%) | 8/8 (100%) a | 0.55 |
Abbreviations: AF‐MSCs, amniotic fluid‐derived mesenchymal stem cells; CRL, crown‐rump length; NA, not available; NR, exact data are not retrievable after contact with corresponding author; P‐MSCs, placental‐derived mesenchymal stem cells; POD, postoperative day.
a
Fetal MMC surgical repair as a control group.